Dendreon (DNDN) posted a narrower Q1 loss, but shares -11.9% premarket as sales of its Provenge...

|About: Dendreon Corporation (DNDN)|By:, SA News Editor

Dendreon (DNDN) posted a narrower Q1 loss, but shares -11.9% premarket as sales of its Provenge prostate cancer vaccine rose 6.5% Y/Y, with low single-digit growth predicted for Q2. Analysts are concerned over the level of sales growth and that profit margins for DNDN’s only approved product aren’t high enough. A Citi analyst says the "only upside" in the stock comes from potential acquisition.